News on genetics and genomics applications in the Ag-Bio, Veterinary, Forensics, Food Safety, and Environmental Testing markets.
Because of COVID-19, the San Diego-based firm said it was unable to ship new instruments and many users were unable to operate their existing ones.
The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
The company holds and licenses a variety of IP related to high-throughput genotyping, sample pooling, and methods involved in oligonucleotide ligation-based assays.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
The genome mapping firm's instrument revenues were down 50 percent year over year in the fourth quarter, offset by an increase in consumables revenue.
